Population pharmacokinetics of tacrolimus in full liver transplant patients: Modelling of the post-operative clearance

European Journal of Clinical Pharmacology

Volumn 61, Issue 5-6, 2005, Pages 409-416

  Antignac, Marie ^a   Hulot, Jean Sebastien ^a   Boleslawski, Emmanuel ^a   Hannoun, Laurent ^a   Touitou, Yvan ^a   Farinotti, Robert ^a   Lechat, Philippe ^a   Urien, Saïk ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Adult patients; Population pharmacokinetics; Tacrolimus; Transplantation

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT; MALE; OPEN STUDY; POPULATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

BAYES THEOREM; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; POSTOPERATIVE PERIOD; TACROLIMUS; TIME FACTORS;

EID: 27644524142     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0933-6     Document Type: Article

References (26)

1. Backman L, Nicar M, Levy M et al. (1994) FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation 57:519-525
2. Beal SL (1992) Conditional estimation methods. In: California NpgUo (ed) NONMEM users guide. San Francisco
3. Boswell GW, Bekersky I, Fay J et al. (1998) Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 21:23-28
4. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schafer A, van Hooff J (1998) Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 30:1271-1273
5. Fukatsu S, Yano I, Igarashi T et al. (2001) Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol 57:479-484
6. Grenier FC, Luczkiw J, Bergmann M et al. (1991) A whole blood FK 506 assay for the IMx analyzer. Transplant Proc 23:2748-2749
7. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM (2002) International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit 24:59-67
8. Hu RH, Lee PH, Tsai MK (2000) Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. Transplant Proc 32:1689-1692
9. Jain AB, Abu-Elmagd K, Abdallah H et al. (1993) Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 33:606-611
10. Jusko WJ (1995) Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit 17:596-601
11. Kershner RP, Fitzsimmons WE (1996) Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 62:920-926
12. Kino T, Hatanaka H, Hashimoto M et al. (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40:1249-1255
13. Kino T, Hatanaka H, Miyata S et al. (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 40:1256-1265
14. Parke J, Holford NH, Charles BG (1999) A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59:19-29
15. Pou L, Brunet M, Andres I, Rodamilans M, Lopez R, Corbella J (1998) Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int 11:8270-8271
16. Sandborn WJ, Lawson GM, Cody TJ et al. (1995) Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology 21:70-76
17. Sasa H, Hashimoto Y, Shimizu T, Inui K (1998) Hepatic extraction of tacrolimus in rats with experimental liver diseases. Biol Pharm Bull 21(6):610-614
18. Satomura K, Ozaki N, Okajima H et al. (1996) Pharmacokinetics of FK 506 in living-related liver transplantation. Transplant Proc 28:1005
19. Sheiner LB, Rosenberg B, Melmon KL (1972) Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 5:411-459
20. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE (2003) Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 9:130-137
21. Undre N, Moller A (1994) Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. Transpl Int 7:815-821
22. Undre NA, Schafer A (1998) Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 30:1261-1263
23. Venkataramanan R, Swaminathan A, Prasad T et al. (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-430
24. Venkataramanan R, Shaw LM, Sarkozi L et al. (2001) Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol 41:542-551
25. Vincent SH, Karanam BV, Painter SK, Chiu SH (1992) In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism. Arch Biochem Biophys 294:454-460
26. Yasuhara M, Hashida T, Toraguchi M et al. (1995) Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 27:1108-1110